Successful treatment with rifampin for fulminant antibiotics-associated colitis in a patient with non-Hodgkin's lymphoma.
A 74-year-old man was admitted to the hospital because of chemotherapy for relapsed non-Hodgkin's lymphoma (NHL). The patient became febrile and experienced diarrhea after chemotherapy. Although ceftazidime and amikacin sulfate were administered as empiric therapy, diarrhea was continued. After several days, stool cytotoxin assay for clostridium difficile (C. difficile) was positive and he was diagnosed as having antibiotics-associated colitis (AAC). Although antibiotics were discontinued and both oral vancomycin and metronidazole were administrated, disease was not improved. To rule out the presence of an additional cause of diarrhea, colon fibroscopic examination was performed. It revealed multiple deep ulcerative lesions at right side colon, surface erosive and minute erosive lesions in all continuous colon. Pseudomembranes were not seen. These findings are compatible with AAC without pseudomembranes. There are no reports that the rifampin is effective on refractory AAC. However, we administered oral rifampin for the current patient. The reasons are 1) conventional antibiotics were not effective, 2) rifampin has excellent in vitro activity against C. difficile, and 3) the efficacy of rifampin on relapsing colitis due to C. difficile is established. After administration of rifampin, fever alleviated and diarrhea was improved. Because AAC may result in significant mortality, patients with refractory or fulminant AAC should be treated with oral rifampin from outset.
Molecular Hematology and Oncology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-0841, Japan. nomuken@sun.kpu-m.ac.jp
Kenichi
K
Nomura
Yosuke
Y
Matsumoto
Naohisa
N
Yoshida
Sawako
S
Taji
Naoki
N
Wakabayashi
Shoji
S
Mitsufuji
Shigeo
S
Horiike
Masuji
M
Morita
Takeshi
T
Okanoue
Masafumi
M
Taniwaki
D000284:Administration, Oral; D000368:Aged; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage*; D016360:Clostridioides difficile / Q000187:drug effects*; D004760:Enterocolitis / Q000188:drug therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications*; D008297:Male; D012293:Rifampin / Q000008:administration & dosage*; D012720:Severity of Illness Index
D000904:Antibiotics, Antitubercular; D012293:Rifampin